SLC5A2 and heart failure: The randomized trials of SGLT2 inhibitors reported improvement in cardiovascular and kidney health, reducing heart failure hospitalizations even in non-diabetic patients with reduced ejection fraction heart failure (Cowie and Fisher, 2020; Fernandez-Fernandez et al., 2020).